ReviewCell communication and signaling : CCS2026
Cavin gene family and caveolae-related disorders: pathogenetic roles and possible mechanisms.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cavins, in concert with caveolins, orchestrate the formation and function of caveolae-specialized invaginations of the plasma membrane involved in mechanotransduction, lipid homeostasis, and cell signaling. The Cavin family comprises four members: Cavins 1-3, which are broadly expressed, and Cavin4, which is muscle-specific. Disruption of Cavin function via genetic mutations, epigenetic silencing, or altered expression is linked to a spectrum of caveolae-related disorders, including lipodystrophy, muscular dystrophies, insulin resistance, and cancer. This review offers a comprehensive analysis of the physiological roles, pathophysiological implications, and therapeutic potential of cavins, with emphasis on their involvement in cancer, metabolic diseases, and muscle disorders, highlighting their value as biomarkers and molecular targets in precision medicine. Specifically, Cavin1 serves as the central structural and functional scaffold of caveolae, linking mechanoprotection, lipid metabolism, and ribosomal RNA transcription to cellular stress adaptation and disease pathogenesis, whereas Cavin2 modulates caveolae morphology and signaling, with emerging roles in insulin sensitivity and inflammatory regulation. Cavin3, in turn, is considered a dynamic regulator of caveolae turnover and signal integration, linking caveolar function to cell signaling, DNA damage responses, and tumor suppression. Finally, Cavin4 plays a critical role in muscle-specific caveolae organization, mechanotransduction, and hypertrophic signaling. In the context of tumorigenesis, cavins together represent promising therapeutic targets due to their capacity to induce apoptosis, inhibit cancer cell migration and invasion, and modulate inflammatory responses; however, their roles appear to be context-dependent, with expression patterns and functional outcomes varying across tissue types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.